Jun 21 2010![NewsGuard 100/100 Score](https://d2jx2rerrg6sh3.cloudfront.net/images/newsguard-100.svg)
Immunomedics Inc. (Nasdaq:IMMU) today announced that clinical trial results from the Phase IIb EMBLEM™ study of epratuzumab, a monoclonal antibody targeting CD22, in patients with moderate-severe systemic lupus erythematosus were presented at the 2010 annual Congress of the European League Against Rheumatism (EULAR) in Rome, Italy.
The title of the presentations, followed by a link to the posters presented, are listed below:
SOURCE Immunomedics Inc.